	US 12,274,746 B2
	Dosing parameters for CD47 targeting therapies to hematologic malignancies
Ravindra Majeti, Stanford, CA (US); Mark P. Chao, Mountain View, CA (US); Jie Liu, Palo Alto, CA (US); Jens-Peter Volkmer, Menlo Park, CA (US); and Irving L. Weissman, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and Forty Seven, LLC, Foster City, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and Forty Seven, LLC, Foster City, CA (US)
Filed on Sep. 7, 2021, as Appl. No. 17/468,265.
Application 17/468,265 is a division of application No. 16/619,387, granted, now 11,141,480, previously published as PCT/US2018/038798, filed on Jun. 21, 2018.
Claims priority of provisional application 62/523,182, filed on Jun. 21, 2017.
Prior Publication US 2021/0401979 A1, Dec. 30, 2021
Int. Cl. A61P 35/02 (2006.01); A61K 31/17 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 31/17 (2013.01); A61K 45/06 (2013.01); A61P 35/02 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01)]

11 Claims

1. A method of treating a patient for Acute Myeloid Leukemia (AML), wherein the method comprises:

(a) administering to said patient an effective dose of Hu5F9-G4,

(b) administering to said patient an effective dose of azacitidine, and

(c) administering to said patient an effective dose of a Bcl-2 inhibitor, wherein the Bcl-2 inhibitor is selected from obatoclax, venetoclax, and gossypol,

thereby treating said patient for AML.